4519 On Other Exchanges
4519 is not on other exchanges.

chugai pharmaceutical co ltd (4519) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHUGAI PHARMACEUTICAL CO LTD (4519)

Related News

No related news articles were found.

chugai pharmaceutical co ltd (4519) Related Businessweek News

No Related Businessweek News Found

chugai pharmaceutical co ltd (4519) Details

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research and development, manufacture, marketing, and distribution of prescription medicines in Japan, Switzerland, and internationally. Its products for oncology include Avastin, Rituxan, Herceptin, Perjeta, Kadcyla, Xeloda, Tarceva, Neutrogin, Alecensa, Zelboraf, Aloxi, and Akynzeo; bone and joint diseases/autoimmune diseases comprise Alfarol, Edirol, Bonviva, Actemra, and Suvenyl; renal diseases consist of Mircera, Epogin, and Oxarol; and transplant, immunology, infectious, and other diseases comprise Tamiflu, CellCept, Pegasys, Copegus, and Sigmart. The company also has various products under development in the areas of oncology, bone and joint diseases, autoimmune diseases, central nervous system, and other diseases. The company has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.

7,275 Employees
Last Reported Date: 02/1/17
Founded in 1925

chugai pharmaceutical co ltd (4519) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥273.0M
President, Chief Operating Officer and Repres...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.
chugai pharmaceutical co ltd
Osaka University and Otsuka Pharmaceutical Agree Comprehensive Collaboration: Joint Research Project with Immunology Frontier Research Center

Osaka University and Otsuka Pharmaceutical Co., Ltd. announced the signing of a comprehensive collaboration agreement for advanced research in immunology between the Osaka University Immunology Frontier Research Center (IFReC) and Otsuka. This agreement allows researchers at IFReC to focus on original basic research areas and, with Otsuka, to develop innovative new treatments therefore contributing back to society with the results of their advanced immunology research. According to the agreement, Otsuka will have access to information regarding results of independent basic research projects at IFReC. Although Chugai Pharmaceutical Co., Ltd., which signed a prior agreement has the right of first refusal on joint research projects and intellectual property. Otsuka can discuss future joint research with IFReC, and receive disclosure about future patent rights in immunology from Osaka University. As part of this agreement, Otsuka will contribute to the research activity expenses of IFReC for a period of 10 years.

Chugai Pharmaceutical Co., Ltd., Board Meeting, Feb 01, 2017

Chugai Pharmaceutical Co., Ltd., Board Meeting, Feb 01, 2017. Agenda: To consider the executive compensation plan of the company; to decide to introduce a restricted stock compensation plan; and to submit a proposal regarding the introduction of the compensation Plan to the 106th Annual General Meeting of Shareholders.

Chugai Pharmaceutical Co. Ltd. Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2016; Provides Earnings Guidance for Year Ending December 31, 2017

Chugai Pharmaceutical Co. Ltd. reported unaudited consolidated earnings results for the year ended December 31, 2016. For the period, the company's revenues were JPY 491,780 million compared to JPY 498,839 million a year ago. Operating profit was JPY 76,884 million compared to JPY 86,784 million a year ago. Profit before taxes was JPY 74,448 million compared to JPY 87,276 million a year ago. Net income attributable to the company shareholders was JPY 53,592 million compared to JPY 61,125 million a year ago. Diluted earnings per share were JPY 97.97 compared to JPY 111.79 a year ago. Total cash flows from operating activities were JPY 38,787 million compared to JPY 62,918 million a year ago. Free cash flows were JPY 4.3 billion against JPY 37.0 billion a year ago. Operating free cash flows was JPY 26.0 billion against JPY 64.6 billion a year ago. Purchase of property, plant and equipment was JPY 30,084 million compared to JPY 18,367 million a year ago. Purchase of intangible assets was JPY 6,247 million compared to JPY 6,472 million a year ago. Core revenues were JPY 491.8 billion compared to JPY 498.8 billion a year ago. Core operating profit JPY 80.6 billion compared to JPY 90.7 billion a year ago. Core net income was JPY 56.8 billion compared to JPY 64.9 billion a year ago. For the year ending December 31, 2017, the company expects revenues of JPY 520,500 million, core operating profit of JPY 92,000 million, core earnings per share of JPY 124.11.


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4519 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4519.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4519 Industry Range
Price/Earnings 39.7x
Price/Sales 4.3x
Price/Book 3.3x
Price/Cash Flow 40.6x
TEV/Sales 4.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CHUGAI PHARMACEUTICAL CO LTD, please visit www.chugai-pharm.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.